PDGF-AA, a Potent Mitogen for Cardiac Fibroblasts from Adult Rats

doi:10.1006/jmcc.1996.0280

Journal of Molecular and Cellular Cardiology

Volume 29, Issue 1, January 1997, Pages 357-368

https://doi.org/10.1006/jmcc.1996.0280 Get rights and content

Abstract

The heart responds to increased haemodynamic load with growth of the ventricles. The rise in ventricle mass is due to increasing mass of the myocytes and proliferation of fibroblasts and smooth muscle cells. The accompanying adaptation and remodelling of the interstitium, e.g. production and composition of the extracellular matrix proteins, determine a physiological or pathophysiological hypertrophy. Fibroblasts play a critical role in this process as the producers of extracellular matrix proteins. So far the growth factors involved are not well defined, and therefore we investigated the effect of platelet-derived growth factor (PDGF) isoforms on cellular proliferation of fibroblasts from adult rat hearts. Unlike other cell types of the cardiovascular system (e.g. smooth muscle cells), PDGF-AA has an extraordinarily high stimulatory effect on cell growth of these fibroblasts. It induces cell division to nearly the same extent and with the same kinetics as PDGF-BB as shown by cell number and flow cytometry. Cardiac fibroblasts do not express an unusually high number of PDGFα-receptors, (15 300 PDGFα-receptors, 24 800 PDGFβ-receptors per cell) which could explain this effect. Theα-receptors display a lower and shorter autophosphorylation after stimulation with PDGF in comparison to theβ-receptors. The activation of the MAP kinase pathway is not different after stimulation with both PDGF isoforms. Interestingly, quiescent cardiac fibroblasts contain a preactivated p70^S6-kinase. The specific drug rapamycin not only inhibits the p70^S6-kinase activation but also PDGF induced cell proliferation for more than 50%. Because the p70^S6-kinase activation is implicated in growth regulation in this cell system, the preactivation of this kinase is discussed to be a possible explanation for the enhanced growth effect of PDGF-AA.

References (0)

Cited by (58)

A mathematical model of immunomodulatory treatment in myocardial infarction
2022, Journal of Theoretical Biology
A heart attack, or acute myocardial infarction (MI) is caused by the acute occlusion of a coronary artery. MI is associated with 30% mortality; approximately half of the deaths occur prior to arrival at the hospital. Reperfusion therapy in the hospital is a medical treatment to restore blood flow through the blocked artery; treatment includes drugs and surgery. However, the damage to the heart muscles through the infarct area is permanent and there is additional damage around the infarct area due to inflammation or insufficient oxygen supply. Approximately half of the patients who survive MI are hospitalized again within one year after reperfusion treatment.
In this paper we develop a mathematical model of MI and use it to assess the efficacy of drugs used, post reperfusion, to reduce the damage caused by inflammation in a region of the left ventricular wall surrounding the infarct area. The mathematical model, represented by a system of partial differential equations. The model variables include myocytes, endothelial cells, neutrophils, macrophages, fibroblasts and cytokines that play a role in the interactions among these cells. The drugs used to in the model include IL-1, TNF- $α$ and TGF- $β$ inhibitors, and the delivery of VEGF. The model is based on mice data. In particular, we find that immunomodulatory treatment with TNF- $α$ and IL-1 inhibitors can significantly increase the low density of myocytes bordering the infarct area by 50–60% and decrease the abnormally high density of ECM in a region surrounding the infarct area.
Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions
2018, Matrix Biology
Citation Excerpt :
Besides the synthetic function of CF, their rate of proliferation is an important determinant of fibrosis. Given the important role of the Pdgfrα pathway on CF during embryonic development, it was not surprising that some isoforms of PDGF strongly promote CF proliferation via Pdgfrα [38]. Further trophic factors, such as fibroblast growth factor 2 (FGF-2), are also known to induce CF proliferation [39].
Fibrosis and remodeling of the right ventricle (RV) are associated with RV dysfunction and mortality of patients with pulmonary hypertension (PH) but it is unknown how much RV fibrosis contributes to RV dysfunction and mortality. RV fibrosis manifests as fibroblast accumulation and collagen deposition which may be excessive. Although extracellular matrix deposition leads to elevated ventricular stiffness, it is not known to which extent it affects RV function. Various animal models of pulmonary hypertension have been established to investigate the role of fibrosis in RV dysfunction and failure. However, they do not perfectly resemble the human disease. In the current review we describe the major characteristics of RV fibrosis, molecular mechanisms regulating the fibrotic process, and discuss how therapeutic targeting of fibrosis might affect RV function.
The Epicardial Signaling Center in Development and Disease
2010, Heart Development and Regeneration
This chapter discusses the epicardial signaling center in development and disease. The processes that occur during midgestational heart development include formation of the epicardium, myocardial growth, coronary vascular development, endocardial cushion formation, ventricular septation, and trabeculation. Other processes that occur in the midgestational heart include development of the atrial–ventricular and outflow tract endocardial cushions. These structures will give rise to the atrioventricular valves (tricuspid and mitral) and outflow tract valves (pulmonary and aortic), respectively. Proper endocardial cushion development is essential for septation of both the atrial and ventricular chambers, as defects in this important process can lead to atrial and ventricular septal defects (ASD and VSD) both in animal models and in several human genetic syndromes. Ventricular septation is further aided by the growth of the muscular interventricular septum, a process that occurs between E14.5 and E16.5 in the mouse. Lastly, trabeculation of the ventricular chambers occurs throughout midgestational heart development. This process patterns the myocardial wall into an outer compact layer and an inner trabecular layer. Little is known about the signals that regulate the formation of these finger-like extensions of myocardial tissue (trabeculae) that project into both the right and left ventricular chambers. An entity termed isolated ventricular noncompaction, which in many individuals leads to fulminant heart failure, results from the overproduction of these finger-like projections at the expense of compact myocardial tissue.
The Epicardial Signaling Center in Development and Disease
2010, Heart Development and Regeneration: Volume I
This chapter discusses the epicardial signaling center in development and disease. The processes that occur during midgestational heart development include formation of the epicardium, myocardial growth, coronary vascular development, endocardial cushion formation, ventricular septation, and trabeculation. Other processes that occur in the midgestational heart include development of the atrial–ventricular and outflow tract endocardial cushions. These structures will give rise to the atrioventricular valves (tricuspid and mitral) and outflow tract valves (pulmonary and aortic), respectively. Proper endocardial cushion development is essential for septation of both the atrial and ventricular chambers, as defects in this important process can lead to atrial and ventricular septal defects (ASD and VSD) both in animal models and in several human genetic syndromes. Ventricular septation is further aided by the growth of the muscular interventricular septum, a process that occurs between E14.5 and E16.5 in the mouse. Lastly, trabeculation of the ventricular chambers occurs throughout midgestational heart development. This process patterns the myocardial wall into an outer compact layer and an inner trabecular layer. Little is known about the signals that regulate the formation of these finger-like extensions of myocardial tissue (trabeculae) that project into both the right and left ventricular chambers. An entity termed isolated ventricular noncompaction, which in many individuals leads to fulminant heart failure, results from the overproduction of these finger-like projections at the expense of compact myocardial tissue.
The Effects of Platelet-Derived Growth Factor in Rat Cardiac Allograft Vasculopathy and Fibrosis
2008, Transplantation Proceedings
We investigated the relationship between expression of platelet-derived growth factor (PDGF) and development of chronic rejection. Rat recipients pretreated by inoculation of donor splenocytes (SPC) followed by cyclophosphamide (CP) were divided into three groups: control animals without immunosuppression (group 1, n = 10); group 2 recipients treated with cyclosporine (n = 10), and euthanized at 2 to 3 months posttransplantation; group 3 (n = 20) animals treated with SPC and CP with 10 recipients euthanized at 2 weeks posttransplantation and 10 monitored for at least 1 year. Immunohistological and pathological studies were performed to evaluate cardiac allograft vasculopathy (CAV), myofibrosis, and expression of PDGF. Allografts collected from group 2 demonstrated abundant infiltration of collagenous fibers in the coronary arteries. Edema and proliferation of the intima as well as the lumial stenosis were revealed in groups 1 and 2. Additionally, immunohistological staining demonstrated a high expression of PDGF protein in cardiac muscles and coronary arteries in groups 1 and 2. In contrast, pretreatment of animals with SPC plus CP induced long-term allograft survival. Importantly, the expression of PDGF in cardiac muscles and arteries in group 3 was significantly less than groups 1 and 2. CAV were dramatically reduced in group 3 when compared with groups 1 and 2. Preconditioning of recipients with SPC and CP suppressed the expression of PDGF within allografts and induced transplant tolerance. Our results suggested that the expression of PDGF plays an important role during the development of cardiac allograft rejection.
Observation of Efficacy and Safety of Converting the Calcineurin Inhibitor to Sirolimus in Renal Transplant Recipients With Chronic Allograft Nephropathy
2008, Transplantation Proceedings
Citation Excerpt :
Sirolimus also has protective effects on endothelium and smooth muscle cells in vascular injury. Therefore, sirolimus may antagonize or relieve the pathological changes of CNI-caused renal fibrosis and endarterial hyperplasia as well as other kinds of CAN.8–13 Cittero13 quickly withdrew CNI in 19 cases of chronic renal allograft dysfunction, substituting sirolimus.
The objective of this study was to evaluate the efficacy and safety of converting from a calcineurin inhibitor (CNI) to sirolimus among renal transplant recipients with chronic allograft nephropathy (CAN).
In 16 patients with CAN, substituted sirolimus for CsA or FK506 and observed the incidence of acute rejection and changes in serum creatinine, triglycerides, cholesterol, blood uric acid, and peripheral blood leukocyte/platelet counts within 12 months. All recipients underwent an allograft biopsy before conversion. The targeted sirolimus level was 4–8 ug/L.
After conversion to sirolimus, the creatinine level of 7 cases decreased and the efficacy rate was (43.8%). No acute rejection occurred during the follow-up. The cases with hypercholesteremia increased from 3 to 7 after conversion; hypertriglyceridemia increased from 3 to 5; leukopenia occurred in 2; subnormal platelet counts increased from 2 to 3; and hyperuricemia increased from 6 to 7. Meanwhile, the average level of peripheral blood leukocytes obviously decreased in the first month, the average peripheral blood cholesterol increased over 12 months, but the average content of peripheral blood platelets, triglyceride and blood uric acid failed to display as statistic difference. Eight patients showed C4d deposition in peritubular capillary in graft tissue before conversion, 7 cases of whom showed no improvement in renal function. In 6 cases there was no C4d deposition in peritubular capillary in graft tissue. Only 2 of 6 cases showed no improvement in renal function. There were 6 patients whose creatinine level was <2.48 mg/dL before conversion, and renal function in 5 of them improved in a year after conversion. In contrast, among 10 patients whose blood creatinine level was >2.48 mg/dL, only 2 cases improved.
It is safe for patients with CAN to use substitute sirolimus for CNI; the incidence of acute rejection did not increase. In this study, 43.8% of patients showed improved renal function. The main adverse reactions after conversion to sirolimus were hypercholesteremia and decreased peripheral blood leukocytes. The serum creatinine level and the deposition of C4d in peritubular capillary were important factors influencing therapeutic efficacy.

View all citing articles on Scopus

^☆: Please address all correspondence to: Andreas Simm, Theodor-Boveri-Institut fü Biowissenschaften (Biozentrum) der Universität, Physiologische Chemie II, AM Hubland, DM-97074 Würzburg, Germany.

View full text

Regular ArticlePDGF-AA, a Potent Mitogen for Cardiac Fibroblasts from Adult Rats☆

Abstract

Regular Article
PDGF-AA, a Potent Mitogen for Cardiac Fibroblasts from Adult Rats☆